文/梧桐晓编 2025年1-3月，沪、深、北三个交易所共受理IPO申报企业只有8家，其中上交所2家，都是科创板，深交所受理1家，申报主板，北交所受理5家。其中申报科创板 IPO的昂瑞微电子报告期累计亏损8.8亿元。申报深交所主板上市的华润新能源为一家设立于中国香港红筹企业，2023年扣非净利润高达82亿元。北交所受理的5 家公司选择的具体上市标准均为《上市规则》第 2.1.3 条第一项：预计市值不低于 2 亿元，最近两年净利润均不低于 1500 万元且加权平均净资产收益率平均不低 于 8%，或者最近一年净利润不低于 2500 万元且加权平均净资产收益率不低于 8%。 8家今年一季度受理的IPO申报企业基本信息 单位：亿元 | 公司简称 | 甲报板块 | 王营业务 | 最近一年 | 最近一年 | 保荐机构 | | --- | --- | --- | --- | --- | --- | | | | | 营收 | 净利润 | | | 昂瑞微电子 | 科创板 | 射频前端芯片、射频SoC芯片及其他模拟芯片的研发设计 | 21.01 | -1.1003 | 中信建投 | | | | 与销售 | | | | | 傲拓科技 ...

Core Viewpoint - The China Securities Index for the medical industry has shown a slight decline over the past month, quarter, and year-to-date, indicating a stable but slightly negative trend in the sector [2]. Group 1: Index Performance - The China Securities Index for the medical industry is currently at 566.67 points [1]. - Over the past month, the index has decreased by 0.49%, while it has seen a minimal decline of 0.02% over the past three months and year-to-date [2]. Group 2: Index Composition - The top ten weighted companies in the index include: - Mindray Medical (14.12%) - Aier Eye Hospital (8.91%) - United Imaging Healthcare (7.39%) - Aimeike (3.93%) - Huatai Medical (3.48%) - New Industries (3.41%) - Yuyue Medical (3.12%) - Shanghai Pharmaceuticals (3.04%) - Meinian Onehealth (2.57%) - Jiuan Medical (2.39%) [2]. - The index's holdings are primarily listed on the Shenzhen Stock Exchange (57.38%) and the Shanghai Stock Exchange (42.62%) [2]. Group 3: Sector Allocation - The sector allocation within the index is as follows: - Medical Devices: 34.29% - Medical Consumables: 23.16% - Pharmaceutical Commerce: 15.33% - Medical Services: 14.26% - In Vitro Diagnostics: 12.95% [2]. Group 4: Index Adjustment Mechanism - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December [3]. - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [3].

Group 1: Major Achievements in Science and Technology - China has made significant advancements in space science, including the detection of gamma-ray bursts from 25.6 billion light-years away and the first measurement of black hole X-ray binary spin and orbital inclination [3][5] - Tsinghua University has developed a brain-like complementary visual perception chip, "Tianmou Chip," which reduces bandwidth by 90% and achieves 10,000 frames per second with high precision and dynamic range [3][5] - Peking University has introduced a new paradigm for crystal preparation, enhancing the purity of materials like graphite and molybdenum disulfide by 10 to 100 times [3][5] - Huayi Quantum has created the world's first commercial prototype of a quantum computing system with over 100 ion qubits, significantly enhancing quantum computing capabilities [3][5] Group 2: Economic Applications - Blue Arrow Aerospace has successfully developed the Zhuque-2 improved liquid oxygen-methane rocket, becoming the first and only liquid oxygen-methane rocket to achieve three consecutive successful launches [5][6] - Beijing University of Posts and Telecommunications has established the world's first space-ground computing test platform, enhancing AI collaboration in satellite operations [6][7] - A collaborative effort has resulted in the development of a 6G prototype system capable of 6.6 Gbps transmission speed and sub-meter level perception accuracy [7][8] - Beiqi Foton has launched a zero-carbon liquid hydrogen heavy truck with a range exceeding 1,000 km, integrating 23 innovative technologies [8][9] Group 3: National Strategic Needs - Tsinghua University has developed a mobile hybrid processing robot that significantly improves processing precision and efficiency for large complex components used in major national projects [10][11] - State Grid Corporation has created a flexible DC converter for offshore wind power, increasing power density by 37% and reducing overall project costs by 15% [11][12] - China National Offshore Oil Corporation has successfully conducted the world's first joint extraction of natural gas hydrates and shallow gas, achieving a daily gas production rate exceeding 100,000 cubic meters [12][13] - A new large-scale high-temperature superconducting coating device has been developed, supporting the domestic production of superconducting electronic devices [13][14] Group 4: Health and Well-being - The "Beijing Brain No. 1" intelligent brain-machine interface system has been developed, achieving over 98% effective channel count for patients with motor function disorders [15][16] - A new covalent technology for radioactive drugs has been developed, increasing tumor delivery efficiency by over 10 times while minimizing side effects [16][17] - A domestic first integrated surgical robot for brain and spine procedures has been created, achieving a positioning accuracy of ≤0.5 mm [17][18] - The first targeted drug for brain glioma, "Bertinib," has been developed, significantly extending patient survival and reducing disease progression risk [18][19] - The ARC biological coupling technology has been introduced, enhancing nitrogen-fixing efficiency and crop yield while controlling mycotoxin production [19][20]

Investment Rating - The investment rating for the company is "Buy" [4][18]. Core Views - The company has released a stock incentive plan for 2025, aiming to solidify growth certainty with a target of 20% year-on-year growth for 2026 [3]. - The U.S. ventilator market is gradually stabilizing, with a projected recovery in 2025, leading to potential high growth for the company [4]. - The domestic business share is steadily increasing, and there is potential for market share growth overseas, particularly in the U.S. and Europe [4]. Summary by Sections Stock Incentive Plan - The stock incentive plan involves granting a total of 704,000 restricted shares, accounting for 0.79% of the company's total share capital of 89.6 million shares, to 54 individuals including senior management and key technical personnel [3]. Financial Performance and Forecast - The company expects revenue for 2024 to decline by 21% to 884 million yuan, with a net profit forecast of 161 million yuan, a decrease of 46% [4]. - Revenue growth is projected to rebound to 30% in 2025 and 28% in 2026, with net profit growth of 28% and 31% respectively [4][5]. - The earnings per share (EPS) is expected to be 1.80 yuan in 2024, increasing to 2.31 yuan in 2025 and 3.03 yuan in 2026 [5]. Market Position and Strategy - The company is positioned as a leading domestic manufacturer of ventilators, with a strong market share in the U.S. and plans for global expansion [4]. - The international business accounted for 60.55% of revenue in the first three quarters of 2024, indicating a growing reliance on overseas markets [4].

转自：北京日报客户端 作为中关村论坛的重要组成部分，2025中关村国际技术交易大会近日召开。在活动现场，《百项新技术 新产品榜单》《百项国际技术交易创新项目榜单》双榜齐发。 "两榜单"进一步聚焦新一代信息技术、新材料、智能装备、医药健康等高精尖产业领域，面向全球40多 个国家和地区征集1472项创新项目，最终评议产生200项新成果，助推前沿科研成果走下"书架"，走 上"货架"，加速产业化落地，展现全球技术交易生态澎湃活力。 硬核科技项目向全球推介 中关村国际技术交易大会正逐渐成为政策首发、成果首秀的国际舞台，本次大会开幕式上持续发布《百 项新技术新产品榜单》《百项国际技术交易创新项目榜单》。今年"两榜单"较往年呈现质量更高、引领 更强等特点。 其中，《百项新技术新产品榜单》旨在展示一批前沿技术产品，推动科研成果走向市场，转化为现实生 产力；《百项国际技术交易创新项目榜单》重点聚焦"国际技术交易合作"，面向全球遴选可转化、可转 移、可交易、可落地的高质量创新技术项目。 比博斯特（上海）汽车电子有限公司凭借其集成式线控制动系统BIBC （One-Box）这一创新成果，成 功跻身两大权威榜单。该项目技术负责人说，从 ...

// 市场要闻 // 国有大行重磅官宣。 3月30日下午，中国银行、中国建设银行、交通银行发布公告称，董事会通过 了向特定对象发行A股股票条件的议案。其中，建设银行拟引入财政部战略投资，募资总额不超过 人民币1050亿元。交通银行拟定增募资不超过1200亿元，发行对象为财政部、中国烟草和双维投 资，其中财政部拟认购金额为1124.2亿元。募资均用于补充核心一级资本。中国银行拟向特定对象 发行A股股票，募集资金总额不超过1650亿元。 社保基金重仓这些股票。 随着上市公司年报密集披露，作为长线资金代表的社保基金 2024 年末重 仓股及持股变动情况浮出水面。 Wind数据显示，截至3月28日，已有938家上市公司披露了2024年年报，其中有133家上市公司（包含2 家未披露年报但已披露2024年末十大流通股东上市公司）的前十大流通股东中出现了社保基金的身影。 2024年四季度，社保基金新进29只个股的前十大流通股东序列，同时对40只个股的持股数量增加。 自由现金流 ETF 近期成为基金行业的一大焦点。 在挖掘基金重仓股上只看净利润不看现金流的策 略，使得许多基金经理在过去三年间积累了大量有关忽视自由现金流的"苦 ...

Group 1 - The core message emphasizes that China remains an ideal and secure investment destination for foreign enterprises, highlighting the mutual benefits of foreign investment in China [2][3]. - As of now, foreign investment in China spans 20 industry categories and 115 subcategories, with a total of 1.24 million enterprises established and an investment amount nearing 3 trillion USD [3]. - Foreign enterprises contribute significantly to China's economy, accounting for one-third of imports and exports, one-fourth of industrial added value, and one-seventh of tax revenue, while creating over 30 million jobs [4]. Group 2 - China's economic resilience provides a stable anchor for investors, with key economic indicators showing growth: industrial added value increased by 5.9%, service production index by 5.6%, fixed asset investment by 4.1%, and retail sales by 4.0% in the first two months of the year [5]. - The consumer confidence index has been rising for three consecutive months, supported by a series of policies aimed at boosting consumption [5]. - Infrastructure investment grew by 5.6% and high-tech industry investment by 9.7%, indicating strong investment momentum [5]. Group 3 - China has a vast consumer market with over 1.4 billion people, including more than 400 million in the middle-income group, driving diverse demands in quality consumption and emerging technology industries [6]. - Major international events like the Boao Forum and the China International Import Expo serve as platforms for foreign enterprises to seize opportunities in the Chinese market [6][7]. Group 4 - The establishment of 22 free trade zones and the reduction of the foreign investment negative list from 190 to 29 items demonstrate China's commitment to opening up its economy [10]. - The "2025 Action Plan for Stabilizing Foreign Investment" outlines 20 specific measures to enhance investment promotion and service support, marking a significant policy initiative aimed at attracting foreign investment [10][11]. - Recent investments by foreign companies in China, such as Boston Scientific and Siemens, reflect a strong commitment to expanding operations in the country [12].

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $9.6 million, an increase of 10% from $8.7 million in Q4 2023 [20] - Gross profit increased to $5.8 million in Q4 2024, up from $4.8 million in the year-ago quarter, with gross margins improving to 60.1% from 55.3% [21] - Operating loss improved by 68% compared to Q4 2023, adjusted for non-cash impairment charges [12] Business Line Data and Key Metrics Changes - Average net revenue per XTRAC device increased by 11% over the previous quarter and 6% over the prior year [10] - Equipment revenue was $3.8 million in Q4 2024, compared to $3.1 million in Q4 2023, driven by strong capital sales in international markets [20] - Gross domestic revenue billings in Q4 were $4.9 million, marking the third consecutive quarter of sequential increase [13] Market Data and Key Metrics Changes - International sales reached $4.1 million in Q4 2024, up 27% from Q3 2024 and up 41% from Q4 2023, representing the highest level of international sales to date [15] - The installed base of TheraClearX devices in the U.S. increased to 144 by the end of Q4 2024, up from 92 at the end of 2023 [14] Company Strategy and Development Direction - The company is focusing on improving the utilization of its machines by removing underperforming units and assisting higher-performing accounts [10] - The strategy includes enhancing direct-to-consumer advertising and in-clinic processes to drive patient appointments and revenue growth [12][13] - The company aims to stabilize financial performance and drive growth through strategic initiatives laid out at the beginning of 2024 [24] Management's Comments on Operating Environment and Future Outlook - Management noted a strong seasonal effect between Q4 and Q1, with Q1 typically being the weakest quarter [17] - The company is optimistic about continued progress in 2025, supported by its current financial position and strategic goals [22][23] Other Important Information - The company secured preauthorization for over 3,700 patients with acne in partner clinics year-to-date [14] - The cash position as of December 31, 2024, was $8.6 million, which includes $1.3 million of restricted cash [22] Q&A Session Summary Question: Clarification on TheraClearX device numbers - Management confirmed that 108 of the 144 TheraClearX devices are in accounts that are billing insurance [27] Question: Types of practices and geographical presence for TheraClearX - Initial uptake was stronger in the Northeast, primarily among small- to medium-sized groups [32] Question: Strength of international markets - Key international markets include Japan, China, South Korea, and the Middle East, with strong growth driven by technology appreciation and clinical efficacy [36][38] Question: Criteria for identifying underutilized accounts - Management explained that approximately 10% of accounts are churned annually based on performance metrics [49] Question: Determining new clinics for device placement - New accounts are identified based on historical patient treatment numbers and previous relationships with the company [60]

Financial Data and Key Metrics Changes - The company reported fourth quarter HIFU revenues of $9.3 million, a 15% increase year over year, reflecting strong adoption of Focal One technology [7] - Total worldwide revenue for the fourth quarter was $21.5 million, representing a 1.1% growth year over year [7] - Full year 2024 global HIFU revenue increased by 15.3% over 2023, while total worldwide revenues for 2024 were $69.2 million, a growth of 5.7% over 2023 [8][9] Business Line Data and Key Metrics Changes - The HIFU segment reported revenues of €23.8 million for the full year 2024, a growth of 15.7% year over year, driven by increased placements and procedure volumes [38] - In the fourth quarter, the Hycean business generated €8.8 million, up from €7.5 million in the same period last year, with disposable revenues growing by 28.5% [39] - The ESWL division saw nominal growth, with revenues of €2.4 million compared to €2.3 million in the previous year [40] Market Data and Key Metrics Changes - The number of Focal One procedures grew approximately 51% in 2024 compared to 2023, with U.S. procedures increasing by about 31% year over year [13] - The company placed its first Focal One systems in Arkansas, Idaho, and Georgia, expanding its presence to over half of all U.S. states [11] Company Strategy and Development Direction - The company aims to focus on high growth market opportunities, particularly in the HIFU segment, while reducing investments in lower growth, low margin businesses [34] - The recent CE mark for Focal One for treating deep infiltrating endometriosis is seen as a significant regulatory milestone, allowing for controlled market entry and further clinical development [6][25] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued growth of the HIFU business, projecting revenue growth of 16-25% year over year for 2025 [46] - The company anticipates that the landmark Hi Fi study will drive demand for Focal One, positioning it as a mainstream treatment option for prostate cancer [47] Other Important Information - The company has entered into clinical studies for the treatment of BPH and pancreatic tumors, indicating a commitment to expanding its HIFU technology into new indications [20][21] - The Centers for Medicare and Medicaid Services finalized a 5.4% increase in the Medicare hospital outpatient payment rate for HIFU procedures, effective January 1, 2025 [17] Q&A Session Summary Question: Can you provide more detail on HIFU sales growth guidance? - Management expects continued demand for Focal One, with a strong pipeline and recurring revenue from procedures and service revenue contributing to projected growth [49][50] Question: What is the intent for the non-core ESWL and distribution business? - The company is transitioning away from non-core distribution products, focusing on high growth HIFU business, but cannot project if it will phase down to zero [51][52] Question: How is the capital equipment purchase pattern from hospitals in 2025? - The sales cycle remains consistent, but the company has adapted its strategy to close deals more effectively, expecting notable growth throughout 2025 [58][60] Question: Has there been an uptick in interest from hospitals since the reimbursement increase? - The reimbursement increase has positively impacted hospital interest in adopting Focal One, as it enhances the financial analysis for adding this treatment to their services [62][64] Question: What is the strategy for endometriosis commercialization? - The company is working with experts to refine clinical development efforts following the CE mark, with plans for a Phase one launch in CE mark countries [71][72] Question: When can we expect data from the pancreatic tumors study? - The PULSE trial is early in patient recruitment, being conducted locally in France, with no specific data timeline provided yet [73][74]

Group 1 - China Telecom reported a net profit of 33.01 billion yuan for 2024, an increase of 8.4% year-on-year, with total revenue of 523.57 billion yuan, up 3.1% [1] - Minfeng Special Paper achieved a net profit of 72 million yuan, a year-on-year increase of 54.09%, despite a revenue decline of 9.82% to 1.46 billion yuan [2] - Kuaiji Elevator's net profit decreased by 8.46% to 132 million yuan, with total revenue falling by 4.93% to 1.58 billion yuan [3] Group 2 - Zhongjian Technology reported a net profit of 356 million yuan, up 23.16% year-on-year, with total revenue of 812 million yuan, an increase of 45.39% [4] - China Communication Technology announced the resignation of Vice President Zhao Xiaodong due to work changes [6] - Honghua Digital received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose the use of idle raised funds in a timely manner [8] Group 3 - Huazhong Shuanghe received a drug registration certificate for Gadobutrol injection, applicable for MRI examinations [10] - Ruihe Co. reported overdue loans totaling 15.2 million yuan due to slow accounts receivable turnover caused by a major client's debt crisis [12] - Lubo Chemical received a dividend of 76.5 million yuan from its subsidiary [13] Group 4 - Sihai Visual plans to use up to 500 million yuan of idle funds to purchase low-risk, short-term financial products [14] - Binjiang Group won the land use rights for two plots at a total price of 7.742 billion yuan [16] - Canan Co. received a utility model patent certificate for a needle sheath feeding mechanism [18] Group 5 - David Medical's subsidiary's medical device registration application was accepted by the Zhejiang Provincial Drug Administration [20] - Rejing Bio obtained 30 overseas qualification certifications for various in vitro diagnostic reagents and instruments [22] - Jincheng Mining signed a contract worth approximately 21.5 million USD for infrastructure support at a Zambian mine [24] Group 6 - Baiyun Mountain's subsidiary received approval for clinical trials of a new herbal tea product [26] - Hunan Haili successfully acquired land use rights for two plots in Yongxing County [28] - Nanshan Aluminum's subsidiary was listed on the Hong Kong Stock Exchange [30] Group 7 - Jinghua New Materials' application for a simplified procedure to issue shares was accepted by the Shanghai Stock Exchange [32] - Ningbo Construction filed a lawsuit for overdue project payments totaling 112 million yuan [34] - Tiantong Co. received a government subsidy of 47.52 million yuan [36] Group 8 - Zhongqi Co. appointed Zhang Zipeng as the new general manager [38] - Ruihu Mold reported a net profit of 350 million yuan, up 73.20% year-on-year, with total revenue of 2.424 billion yuan [40] - Mega Chip reported a net profit of 211 million yuan, a year-on-year increase of 26.30%, with total revenue of 2.139 billion yuan [42] Group 9 - Shenhuo Co. reported a net profit of 4.307 billion yuan, a decrease of 27.07% year-on-year, with total revenue of 38.373 billion yuan [44] - Feikai Materials plans to acquire 100% of JNC Suzhou and related patents for a total consideration of 3.7 billion yuan [46] - Junpu Intelligent announced that its major shareholders committed not to reduce their holdings for 12 months [48] Group 10 - Yaxing Anchor Chain confirmed that its production and operations are normal amid market interest in marine economy concepts [50] - Guangzhou Development plans to invest 5.612 billion yuan in a coal power environmental replacement project [52] - Ruihu Mold intends to issue convertible bonds to raise up to 880 million yuan for various projects [54]